Milestone Pharmaceuticals Inc.
MISTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 20, 2026 | Cantor Fitzgerald | $3.00(+178%) | $1.08 | TheFly | |
| Apr 10, 2026 | Raymond James | $6.00(+194%) | $2.04 | TheFly | |
| Dec 16, 2025 | Wells Fargo | Mohit Bansal | $8.00(+242%) | $2.34 | TheFly |
| Dec 15, 2025 | H.C. Wainwright | Brandon Folkes | $8.00(+211%) | $2.58 | TheFly |
| Apr 22, 2022 | Piper Sandler | $10.00(+40%) | $7.15 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2026 |
| Wells Fargo | maintain | Overweight | May 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 6, 2026 |
| Wells Fargo | maintain | Overweight | Dec 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 15, 2025 |
| TD Cowen | upgrade | Hold →Buy | Dec 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| Piper Sandler | maintain | Overweight | Mar 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 26, 2024 |
| TD Cowen | maintain | Outperform | Dec 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| Jefferies | downgrade | Buy →Hold | Jun 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 23, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2023 |
| Oppenheimer | maintain | Outperform | Apr 12, 2023 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.21 | $-0.20 | $559.0K | $816.7K |
| May 13, 2026 | $-0.20 | $0.06 | $238.0K | $30.1M |
| Mar 20, 2026 | $-0.16 | $-0.18 | $1.5M | $37.5M |
| Nov 12, 2025 | $-0.12 | $-0.17 | — | — |
| Aug 12, 2025 | $-0.20 | $-0.18 | — | — |
| May 14, 2025 | $-0.31 | $-0.19 | — | — |
| Mar 13, 2025 | $-0.19 | $-0.15 | — | — |
| Nov 12, 2024 | $-0.14 | $-0.16 | — | — |
News
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 33,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of one new emplo…
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the third quarter ended September 30, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30 am ET.
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data showing that CARDAMYST® (etripamil) nasal spray converted approximately two-thirds of patients who experienced recurrent symptomatic paroxysmal supraventricular tachycardia (PSVT) after a prior catheter ablation to normal heart rhythm within 30 m…
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data and program updates for CARDAMYST® (etripamil) nasal spray for its approved PSVT indication and on etripamil nasal spray for an investigational indication will be presented at three upcoming cardiovascular medical meetings:
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR
MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR), has…
Shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences.
MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives and quality of life in the periods between episodes.
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial uptake versus low-cost generics. MIST's Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage, with only ~20% of the PSVT market covered. Financial health is deteriorating: $170M cash, $39M 1H burn, liabilities doubled to $163M, and equity fell to $18M amid high SG&A and compounding royalty debt.
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray